Oligonucleotide Synthesis Market Projected to Surpass USD 26.3 Billion by 2031, Witnessing 17.4% CAGR Growth

Global Oligonucleotide Synthesis Market size was valued at around USD 7.3 billion in 2023 to reach a value of USD 26.3 billion by 2031, at a CAGR of 17.4% over the forecast period (2024-2031).
Global Oligonucleotide Synthesis Market [https://www.skyquestt.com/report/oligonucleotide-synthesis-market] size was valued at around USD 6 billion in 2022 and is expected to rise from USD 7.3 billion in 2023 to reach a value of USD 26.3 billion by 2031, at a CAGR of 17.4% over the forecast period (2024-2031).

Oligonucleotide synthesis market has been witnessing notable progress due to rising demand for customized oligonucleotides in diagnostics, research purposes, and therapeutics impacted by the growing number of improvements in genomics and personalized medicine. Moreover, modernizations in synthesis technology, comprising high throughput and automation are reducing costs and improving efficiency. The market is also driven by expanding applications in life sciences and the growing demand for synthetic biology.

Rising interest in genomics and personalized medicine is significantly impacting the need for custom-made oligonucleotides. High-throughput and automation technologies are also improving the efficiency of synthesis and its scalability. This makes these processes more cost-effective and faster. Another trend witnessed in the market is the growing emphasis on oligonucleotide-enabled treatments like RNA interference and antisense oligonucleotides, which is speedily gaining prominence. The progress and expansion of synthetic biology is offering fresh avenues for the use of oligonucleotide in molecular diagnosis and gene editing. In addition, rising focus on tailored solutions and high-quality products to cater to certain clinical and research needs is trending in the market.

Get a Free Sample Research Report:

https://www.skyquestt.com/sample-request/oligonucleotide-synthesis-market

Oligonucleotide Synthesis Market Segmental Analysis

Global Oligonucleotide Synthesis Market is segmented by Product, Application, End User, and region.

Based on Product, the market is segmented into Oligonucleotide-based Drugs (Antisense Oligonucleotide-based drug, siRNA oligonucleotide-based drug, Other oligonucleotide-based drug), Synthesized Oligonucleotides (Primers, Probes, DNA Oligos, RNA Oligos, Other Synthesized Oligos (Customized Oligos, Predesigned Oligos), Reagents & Consumables, and Equipment.

Based on Application, the market is segmented into Therapeutic Applications (Disease Type (Neurological Disorders, Rare Diseases, Other Diseases), Research Applications (PCR, Sequencing, Other Research Applications), and Diagnostic Applications.

Based on End User, the market is segmented into Hospitals, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, CROs and CMOs, Academic Research Institutes.

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Integration with CRISPR Technology to Drive Innovations in Synthesis and Designs

A number of improvements and developments are witnessed in the oligonucleotide synthesis market, including advanced synthesis methods, customized alternatives, and integration with CRISPR-like technologies. The improvements in enzymatic methods and solid-stage synthesis are growing prominence and decreasing the rate of mistakes. Improved capabilities for customized design of oligonucleotide are useful for certain dedicated therapeutic and research requirements, enabling for more accurate applications. Moreover, the growth of (NGS) next-generation sequencing is fueling the demand for superior quality oligonucleotides for target sequencing and library preparation. This also comprises emphasis on oligonucleotides in applications like CRISPR gene-editing, thus impacting innovations in synthesis and design. To support this, companies are also capitalizing in scalable manufacturing process to satisfy the mounting demand for therapeutic oligonucleotides.

* In May 2024, Eurofins Genomics US, launched a modernized novel solution that allows the development of oligos at an appealing price-point, mainly democratising the DNA and enhancing accessibility of oligos to all for research purposes.
* In December 2022, Merck signed a non-binding MoU with Synplogen, a new entrant. Both businesses will work with the objective of combining their competencies to offer simplified manufacturing, testing, and development of viral vector gene treatments for Japan.
* In June 2022, Agilent Technologies Inc. unveiled its improved software, named 'MassHunter BioConfirm 12.0'. It supports the data produced by Agilent high-resolution LC/MS for better purity analysis of oligonucleotide and sequence validation.
* In October 2023, Integrated DNA Technologies (IDT), an operating Life Sciences department of Danaher Corporation pronounced the accomplishment of its novel facility for Therapeutic Oligonucleotide Manufacturing in Coralville, lowa. This entry in therapeutics space allows IDT to produce research products using cGMP gene therapy and grade cell reagents to offer research people with sole companion that helps speedy transition from laboratory to therapeutic progress.

Ask for Customization:

https://www.skyquestt.com/speak-with-analyst/oligonucleotide-synthesis-market

The report covers the following players:

* Danaher Corporation
* Thermo Fisher Scientific Inc.
* Merck KGaA
* Eurofins Scientific
* Agilent Technologies, Inc.
* Kaneka Corporation
* Azenta, Inc.
* Sarepta Therapeutics, Inc.
* AstraZeneca
* Astellas Pharma Inc.
* Jazz Pharmaceuticals PLC
* Nippon Shinyaku, Co. Ltd. (NS Pharma, Inc.)
* Ionis Pharmaceuticals, Inc.
* Novartis AG
* OligoMaker ApS (Part of TAG Copenhagen A/S)
* Biolegio BV
* Biolytic Lab Performance, Inc.
* Bio-Synthesis, Inc.
* Creative Biogene
* Reprocell, Inc.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/oligonucleotide-synthesis-market

This report covers the following segments:

* A. Product
* Oligonucleotide-Based Drugs (Antisense Oligonucleotide-based drug, siRNA oligonucleotide-based drug, Other oligonucleotide-based drug)
* Synthesized Oligonucleotides (Primers, Probes, DNA Oligos, RNA Oligos, Other Synthesized Oligos (Customized Oligos, Predesigned Oligos))
* Reagents & Consumables
* Equipment

* B. Application
* Therapeutic Applications [Disease Type (Neurological Disorders, Rare Diseases, Other Diseases)]
* Research Applications (PCR, Sequencing, Other Research Applications)
* Diagnostic Applications

* C. End User
* Hospitals
* Pharmaceutical & Biotechnology Companies
* Diagnostic Laboratories
* CROs and CMOs
* Academic Research Institutes

Escalating Demand for Personalized Medicine and Expanding Applications to Further Propel Market

In summary, the market for oligonucleotide synthesis presents an evolving and dynamic ecology combining medicine, technology, and science. As research is engaged in unlocking complete potential of nucleic acid-enabled therapies and tools, the need for quality and customized oligonucleotides will further increase. This impact innovation and fuels the industry towards more personalized healthcare and precision medicine.

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oligonucleotide-synthesis-market-projected-to-surpass-usd-263-billion-by-2031-witnessing-174-cagr-growth]
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/oligonucleotide-synthesis-market



This release was published on openPR.